aXichem AB (publ). which develops and markets natural analogue industrial chemicals, announces that the European Food Safety Authority (EFSA) has informed the company that the authority needs additional time to review the company's application for Feed Additiveapproval in the EU for the product phenylcapsaicin as a feed ingredient, under the brand name aXiphen ®. EFSA communicates that the new date for a statement is 5 August 2023.
" We have not received any new questions or other demands from EFSA, but only a new time for when they see it possible to come up with a statement. My assessment is that it is about EFSA's planning and resources and that they want to ensure quality throughout processing. We would of course have liked to receive an announcement at the previously stated time, but all in all it does not change our launch plans for aXiphen in Europe," says Torsten Helsing, CEO of aXichem.
About phenylcapsaicin and aXiphen The health benefits of chili, with its active ingredient capsaicin have been known for centuries. aXichem’s proprietary molecule, phenylcapsaicin, combines the naturally occurring phenyl group with capsaicin, bridged by a triple bond. The result is an innovative natural analogue capsaicin with high purity, where the pungency is greatly reduced.
Production tests and studies have proven the effectiveness of aXiphen® as an ingredient in poultry feed. A production test on on-floor salmonellaprevalence, following the inclusion of 15 ppm phenylcapsaicin in a regular starter diet, was carried out in a full-scale commercial broiler production trial under farming conditions. The production test included about 1.6 million broiler chickens. The trial concluded that under the conditions of the test, the inclusion of 15 ppm phenylcapsaicin in broiler chicken feed statistically significantly reduced the number of farms with salmonella-positive floor boot swabs. The European model for production efficiency, EPEF, showed that breeding efficiency increased by 14% compared to traditional feeding.
This information is such that aXichem AB is obliged to publish in accordance with the EU Market Abuse Regulation. The information was submitted, through the care of the contact person below, for publication on 13 June 2023, at 20:45 CET.